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CARDIAC ARRHYTHMIA SUPPRESSION TRIAL (CAST): BASELINE 
PREDICTORS OF HIGHEST MORTALITY 
Edward V. Platia, Richard W. Henthorn, Yudi Pawitan, 
Thomas A. Buckingham, Mark D. Carlson, Jeffrey L. 
Anderson, Peter E. Carson, and CAST Investigators 
Washington Hospital Center, Washington, D.C. 
As part of the CAST, we analyzed clinical and labor- 
atory baseline variables, and found that the 755 patients 
(pts) treated with flecainide and encainide (PLEC/ENC) 
and the 743 pts receiving placebo were similar. Our ob- 
jective was to determine which variables reflected the 
greatest disparity in mortality between pts treated with 
PLEC/ENC and those treated with placebo. We calculated 
relative risk (RR) of total mortality for each variable, 
at an average of 10 month followup. For each of the var- 
iables examined, the total mortality was greater for FLEC/ 
ENC compared to placebo pts. However, there were several 
univariate predictors of particularly high RR: (all p( 
.0004) : The highest RRS were observed in pts with a non-Q 
wave MI (RR=9.1), history of prior MI (RRa3.1) or angina 
(RR=2.8), and heart rate >74/min (RR-3.0). The only sig- 
nificant interaction was found between FLEC/ENC and Q 
wave abnormality (~1.03). The significance is nominal 
because it is not adjusted for multiple comparison. 
In conclusion, although FLEC/ENC treatment was asso- 
ciated with higher mortality with respect to all baseline 
variables measured, the risk was greatest in pts with non- 
Q wave HI. This supports the hypothesis that a possible 
interaction between potentially jeopardized myocardium 
and FLEC/ENC was important in increasing mortality in 
the CAST. 
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INCREASED POTENTIAL FOR REGRESSIOE( OF POST-PTCA 
RESTENOSIS USING INTENSIVE LIPID-ALTERING THERAPY: 
COMPARISON WlTH MATCHED NON-PTCA LESIONS 
Stewart DK MD, 
Albefs JL, Brown El0 MD PhD 
Cardiology Divisbn, University of Washington, Seattle, Washington 
To determine the potential for ‘late” regression of lesions r 6 months posl- 
PTCA, we studied 18 such lesions in 16 patienls with basetine catheterlzalion 
7 f 4 months post-PTCA 
were among those pattici 
t follow-up cath 2.5 yre later. These patients 
in the FATS Trial. All had age 5 62, apoB r 
125 n&Ml, positiie family history, and established coronary disease. All had 
been randomly assigned to L+C: Lovastatin 20 mg bid plus colestipol: N+C: 
Niacin 1 gm qid plus colestipol; or CONV: placebos (or colestipol 10 mg tid H 
LDLc was elevated). QuanMaOve coronary arteriography demonstraled 
modest restenosis, 40% f 9 immedialely post-PEA to 45% f 15 at baseline, 
among lhese lesions. For each post-PTCA lesion 13 non-PTCA lesions were 
Selected, matched for lipid phenotype, LDLc, HDLc, and baseline stenosis 
severity. The severity of the 18 PTCA, and 202 non-PTCA lesions was 
measured in blinded fashion at baseline and 2.5 years later. LDLc and HDLc, 
esse$ally unchanged by COW, changed substatially with N+C (-45%, &%) 
a$ wah L+C W%, +16%). Results are expressed as change (k SD) In % 
aameter stenosis between these two lime points 
lesion reoression bv at least lO%S fRi? 
(d%S2.5), and frequency of 
EEsul& - CONV I- N+C- LtC 
bl 
-.- 
BE bl 
Non-PTCA Les. 40 
BE 
5% 31 10% 131-2&B 12% 
PTCA Les. 6 125 0% 4-14xtf10 75%‘+ 8-14’*k863%‘+ 
chiquare comparison: Versus non-PTCA: l pcO.OS “p4.01 
Versus Conv: +p<o.os 
. 
was significantly 
* Late regression of residual stenosis among PTCA lesions 
greater in frequency and magnitude lhan that among a 
.!natch.sd s!! of non-PTCA lesions. This occurred only among patients taking 
Intenstve bptd-allering therapy. These findings suggest lhat such therapy 1) 
may be effective as primary therapy for significant but symptomatically stable 
festerUs, and 2) might retard restenosis. 
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Differences in the Progression of Coronary Ar- 
tery Disease between the Three Major Coronary 
Arteries - Results from the INTACT-study 
Stefan Jost, Wolf Rafflonbeul, Jaap Deckers, 
Peter Nikutta, Birgitt Wiese, Paul R. Lichtlen, 
and the INTACT-Group. Hannover Medical School, 
Hannover, FRG 
The progression (PRO) pattern in the three 
major coronary arteries was analyzed from the 
data of the prospective INTACT-study. In IN- 
TACT, 348 pts underwent repeated coronary an- 
giography under standardized conditions within 
three years. The angiograms were quantitatively 
analyzed using a computer-assisted edge detec- 
tion system (CAAS). A coronary stenosis (ST) 
was defined as diameter reduction 20%. A total 
of 4848 coronary segments and 1063 ST were com- 
pared between the angiograms. PRO of coronary 
artery disease was defined as reducti 
minimal diameter of preexisting ST by 
(two-fold standard deviation of the method), as 
well as by development of new ST at previously 
normal sites. The incidence of PRO in the right 
coronary artery (RCA), circumflex (CX) and left 
anterior descending (LAD) artery is depicted in 
the table: A = ST with PRO; B = new ST/seament 
cx _ LAD ’ - 
Tkuii PRO of preexisting ST, as well as the de- 
velopment of new ST was most frequent in the 
RCA. Revascularization measures should consider 
the particularly rapid PRO of the RCA. 
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TS OF APPARENTLY L 
ENTS WITH CORONARY Y 
Tommy C. Lee, Michael L. Stadius, Edwin L. Alderman, 
We evaluated angiographically no I coronary segments in patients (Pts) 
with visually evident coronary artery disease (CAD) elsewhere using 
quantitative coronary arteriography. We examined 136 angiograms of male Pts 
with CAD 10 Mentii visibly normal segments of the left main (LM) and proximal 
portions of the left antetior descending @LAD), lefl circumflex (pLCX) and right 
coronary (pRCA) arteries. Normal segments were grouped according to Ihe 
proximity of the CAD elsewhere. Normal segments wllhout any visible disease 
in the same vessel, but with CAD present in other vessels, comprised the 
Distant CAD group. For the LM, this meanl no disease in both the LAD and 
LCX vessels. Conversely, normal segments with visible disease elsewhere 
within the same vessel were considered lo have Adjacent CAD. For the LM, 
this meant disease in the LAD and/or LCX. Normal segments with visibly 
abnormal adjacent segments comprised the /mmediate/y &&cent CAD group. 
Normal segments with visibly normal intervening segments between the 
normal-appearing proximal segment and distal disease comprised the 
Adjacent but Distal CAD group. Entirely normal angbgrams from 26 age- 
matched males with atypical chest pain were used as controls. All segments 
’ pd.05 vs Control; $ pcO.05 vs Distant CAD; Q ~~0.05 vs Adjacent but Distal CAD 
Conclusions: In CAD Pls, apparently normal coronary segments have smaller 
luminal diameters compared to similar segments in Pls wilh no evidence of CAD. 
These findings am wnslstenl wllh the presence of dlse CAD in the otherwise 
apparently normal segments from the CAD pts. Quantitative angiographic 
techniques are useful in detecting abnormalities in coronary artery diameters 
which most likely reflect lhe presence of early, otherwise inappamnl, CAD. 
